Here are all todays headlines related to Mediclinic International News. If you wish to drill deeper to view past Mediclinic International News items, follow the next 20 headlines link at the foot of the page.
Britvic: Berenberg upgrades to buy with a target price of 900p.
Hospital operator Mediclinic International kept its dividend flat as it reported a £492m loss after changes in the Swiss regulatory environment led to considerable non-cash write downs.
Mediclinic International said it expects profits for the year to be marginally ahead of expectations, thanks to a "significant" second half improvement in its Middle East and Southern Africa hospitals.
Private healthcare services group Mediclinic announced on Thursday that Ronnie van der Merwe will be installed as chief executive and an executive director from 1 June.
1645: After starting in the red, the FTSE 100 has steadily strengthened as the session wore on. It finished at 7,281.57, up 34.8 points or 0.48%.
Here's a closing comment from market analyst Joshua Mahony at IG. "With a morning's worth of disappointing eurozone PMI surveys, we have seen Carney's inflation report testimony drag EURGBP lower despite today's jump in UK unemployment. While Carney's expectation of three rate rises over the next three years will grab the headlines, the fact that the bank aims to be 'nimble' given Brexit uncertainty points towards a strong chance we may never see all three hikes materialise should a preferential deal not be achieved."
Looking towards US monetary considerations, given the impending release of FOMC minutes, he added: "Coming at a time where economic growth and tax-cut fuelled wage jumps are pushing inflation expectations higher, markets will be keeping a keen eye out for a signal of just how tolerant members will be should inflation continue to rise."
Like the day before, it was some of the more defensive issues in the market that bore the brunt of selling despite the rout in equities worldwide, with recent slight shifts in expectations for policy tightening by the Federal Reserve in 2018 apparently triggering a sharp rise in stockmarket volatility as government bonds markets in the US, and elsewhere, came under pressure.
UBS downgraded Mediclinic to 'neutral' from 'buy' as the risk-reward ratio "now looks more balanced" and the stock recovered from its low in November.